B+
Bull case
25%
Probability
Target price
$25.00
Analysis reference price unavailable
Analysis 2026-09-24 · RankAlpha Sentiment Codex
JBIO
Jade BiosciencesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The Phase 1 JADE101 IgA reduction and tolerability signal supports further testing, while Phase 2 is underway and $461.2 million of June 30 cash, cash equivalents and investments was projected by Jade to fund operations into fourth-quarter 2028. Successful patient data could materially improve the case.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -10.5.
What can break
Clinical expansion across JADE101, JADE201 and JADE301 could increase spending; Jade's stated runway into fourth-quarter 2028 depends on current operating plans. [#SEC-8K-2026-08-10]
Momentum
13
Value
41
Sentiment
51
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $13.00 · Bull $25.00 · Bear $6.00Analysis 2026-09-24; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-24 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-26
Investment thesis
As of 2026-10-26
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $49.89
Why
Momentum13 · Δ7d +6.8
Value41 · Δ7d -0.0
Sentiment51 · Δ7d -10.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -10.5.
Contradictions & invalidation
- • Clinical expansion across JADE101, JADE201 and JADE301 could increase spending; Jade's stated runway into fourth-quarter 2028 depends on current operating plans. [#SEC-8K-2026-08-10]
- • FDA feedback or trial requirements could delay or alter Jade's planned first-half 2027 JADE101 Phase 3 start. [#SEC-8K-2026-08-10]
- • JBIO remains a pre-commercial, trial-dependent company.
Catalyst clock
2026-12-31
JADE301 Phase 1 initiation in fourth-quarter 2026
Lead driver: Sentiment · See AI snapshot
Momentum
13
8% active weight
Current posture
7d trendImproving
Δ7d
+6.8
Δ21d
+10.1
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.4
Sentiment
51
45% active weight
Current posture
7d trendSoftening
Δ7d
-10.5
Δ21d
-12.2
Why this grade
Composite grade D. Momentum 13.2 / Value 40.6 / Sentiment 50.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-24. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$13.00
Analysis reference price unavailable
Analysis 2026-09-24 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-09-24 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$937.43M
Beta
0.88
Shares Out
63.6M
P/E (TTM) · Derived
-3.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-6.21
Rev YoY
-
EPS YoY
-33.0%
Gross Margin
-
Op Margin
-
Net Debt
-$335.43M
Current Ratio
14.93
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data